<DOC>
	<DOC>NCT00241423</DOC>
	<brief_summary>The purpose of this study is to test the hypothesis that in patients with type 2 diabetes, the addition of exenatide will result in lower time-averaged serum glucose during a 24-hour period, compared with placebo.</brief_summary>
	<brief_title>Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Subject has an HbA1c between 7.0% and 10.0%, inclusive. Subject has a body mass index (BMI) &gt;25 kg/m^2 and &lt;50 kg/m^2. Subject is on a stable dose of metformin or metformin plus a thiazolidinedione. Subject has been treated with any of the following medications: *exogenous insulin for more than 1 week within 3 months of screening, *sulfonylureas or meglitinides within 2 months of screening, *alphaglucosidase inhibitors within 2 months of screening, *pramlintide acetate injection within 2 months of screening. Subject has received exenatide, GLP1 analogs, DPPIV inhibitors, or has participated in this study previously.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>